Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
Healthcare
$0.41 +0.49%
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
52W Low $0.82High $4.08
Volume 7.09M
Average 4.03M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
$67.99M
FY 2025 · Annual
Investing Cash Flow
-$7.93M
FY 2025 · Annual
Financing Cash Flow
$72.93M
FY 2025 · Annual
+46.8% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (282.02M) | (92.56M) | (51.93M) | (69.41M) | (5.35M) |
| Depreciation & Amortization | 36.13M | 37.7M | 41.85M | 37.5M | 1.27M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 22.74M | 17.85M | 9.32M | 7.78M | 11.28M |
| Change in Working Capital | (105.61M) | (1.44M) | (20.73M) | (39.68M) | 16.47M |
| Accounts Receivables | (24.03M) | 11.7M | 994K | 4.05M | (14.14M) |
| Inventory | (24.95M) | 19.79M | (2.54M) | (28.4M) | (23.13M) |
| Accounts Payables | (11.74M) | 1.5M | (5.24M) | (1.36M) | 3.08M |
| Other Working Capital | (44.9M) | (34.42M) | (13.94M) | (13.96M) | 50.66M |
| Other Non-Cash Items | 98.54M | (34.7M) | (1.9M) | 23.15M | 44.31M |
| Operating Cash Flow | (252.97M) | (73.15M) | (23.38M) | (40.66M) | 67.99M |
| Capital Expenditures | (59K) | (114K) | 0 | (33K) | (291K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 40M | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | (7.93M) |
| Investing Cash Flow | 39.94M | (114K) | 0 | (33K) | (7.93M) |
| Debt Repayment | 44.78M | (33M) | (32M) | 7.9M | 4.63M |
| Common Stock Issued | 88.95M | 7.53M | 6.79M | 42.65M | 68.36M |
| Common Stock Repurchased | 0 | 0 | 0 | (1.27M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 40.07M | 1K | 385K | (63K) |
| Financing Cash Flow | 133.73M | 14.6M | (25.21M) | 49.66M | 72.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (79.29M) | (58.67M) | (48.59M) | 8.97M | 132.99M |
| Free Cash Flow | (253.02M) | (73.27M) | (23.38M) | (40.69M) | 67.99M |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$5.3M
+ D&A$1.3M
+ Stock-Based Comp$11.3M
+ Deferred Tax$0
+ Working Capital$16.5M
+ Other Non-Cash$44.3M
= Operating Cash Flow$68.0M
- Capex-$291.0K
= Free Cash Flow$68.0M
Analysis
FY2025 free cash flow is $68.0M. FCF conversion is -1272.1% of net income. Operating cash flow was $68.0M, with capex of -$291.0K. The largest bridge item is Other Non-Cash at $44.3M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 5, 2026 | |
| 10-Q | Quarterly report | Nov 5, 2026 | |
| 8-K | Current report | Oct 23, 2026 | |
| 8-K | Current report | Oct 14, 2026 | |
| 4 | Statement of changes in beneficial ownership | Aug 10, 2026 |
Does AKBA generate free cash flow?
Akebia Therapeutics, Inc. (AKBA) generated $67.99M of free cash flow in fiscal 2025.
How much operating cash flow does AKBA produce?
Operating cash flow was $67.99M, before capital expenditures of $291,000.00.
Continue the stock analysis
Jump to another research area for this company.